Invivo Therapeutics (NVIV) Sees Large Volume Increase

Shares of Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) saw unusually-strong trading volume on Friday . Approximately 1,831,639 shares traded hands during trading, an increase of 1,011% from the previous session’s volume of 164,865 shares.The stock last traded at $2.40 and had previously closed at $2.10.

The firm has a market capitalization of $15.91 million, a PE ratio of -0.12 and a beta of 2.12.

Invivo Therapeutics (NASDAQ:NVIV) last issued its earnings results on Tuesday, August 7th. The biotechnology company reported ($7.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($7.07). Equities analysts expect that Invivo Therapeutics Holdings Corp will post -11.58 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in Invivo Therapeutics stock. Stonepine Capital Management LLC bought a new position in shares of Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 77,900 shares of the biotechnology company’s stock, valued at approximately $132,000. Invivo Therapeutics makes up 0.1% of Stonepine Capital Management LLC’s portfolio, making the stock its 25th largest position. Stonepine Capital Management LLC owned about 4.72% of Invivo Therapeutics as of its most recent filing with the SEC. 9.07% of the stock is currently owned by institutional investors.

About Invivo Therapeutics (NASDAQ:NVIV)

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord.

Read More: What is Compound Annual Growth Rate (CAGR)?

Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply